Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Cepheid.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
AIDS Clinical Trials Group
Information provided by (Responsible Party):
Cepheid
ClinicalTrials.gov Identifier:
NCT01587469
First received: April 24, 2012
Last updated: April 30, 2012
Last verified: April 2012

April 24, 2012
April 30, 2012
April 2012
Not Provided
  • Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear positive and MGIT culture positive for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear negative and MGIT culture positive for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Proportion of US participants with Xpert MTB/RIF Assay MTB negative in sputum #1 who are MGIT culture negative for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01587469 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects

This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB. The sensitivity and specificity of the Xpert MTB/RIF (Mycobacterium tuberculosis/rifampin) assay performed on the first sputum collected for Xpert testing will be compared to gold standard conventional culture methods on two sputum specimens, in HIV-infected and HIV-uninfected participants.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Samples of sputum may be retained

Non-Probability Sample

HIV-1-infected and -uninfected men and women, 18 years and older, pulmonary TB suspects who have either a) smear positive sputum or b) clinical suspicion of pulmonary TB including one or more self-reported symptoms of cough, night sweats, weight loss, or fever. Within the 180 days prior to collection of the initial sputum sample, participants will have received none or fewer than 48 hours of TB treatment and, in those 48 hours, fewer than three doses of TB treatment.

Tuberculosis
Not Provided
HIV-infected and -uninfected individuals
HIV-infected and -uninfected individuals with suspected TB infection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1634
Not Provided
Not Provided

Inclusion Criteria:

  • Suspected pulmonary TB (more information on the criterion can be found in the protocol)
  • Men and women age equal to or greater than 18 years
  • Ability and willingness of candidate or legal guardian/representative to provide informed consent
  • Collection of two sputum samples for AFB smear and culture collected within 7 days prior to entry.
  • Availability of two samples for Xpert MTB/RIF testing collected within 7 days prior to entry.
  • Determination and/or documentation of HIV status
  • For HIV-positive candidates, a CD4+ cell count obtained within 45 days prior to study entry or drawn at the time of entry at any laboratory that has a CLIA certification or its equivalent.

Exclusion Criteria:

  • Either receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment within 180 days prior to completion of second sputum collection for Xpert testing
  • Receipt of more than 7 cumulative days of antibiotics intended for bacterial treatment that may have anti-tuberculosis activity, within the 14 days prior to first sputum collection
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Both
18 Years and older
No
Not Provided
United States
 
NCT01587469
ACTG A5295
Not Provided
Cepheid
Cepheid
  • AIDS Clinical Trials Group
  • Centers for Disease Control and Prevention
Study Chair: Annie Luetkemeyer, MD San Francisco General Hospital
Study Chair: Cynthia Firnhaber, MD University of Witwatersrand, South Africa
Cepheid
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP